FDA Approved: COARTEM — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for COARTEM (artemether and lumefantrine) submitted by Novartis, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Coartem (artemether-lumefantrine)

Snippet

SUPPL AP for COARTEM (ARTEMETHER AND LUMEFANTRINE)